A Phase 2/3 interventional study of Immune Globulin Infusion (Human), 10% and Recombinant human hyaluronidase in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 10 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 2/3, and was the 9th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Takeda
Ages 6+
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 14 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 47 across the 18 interventional studies, 113 across the 4 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to acquire additional data on safety and tolerability of recombinant human hyaluronidase (rHuPH20) facilitated subcutaneous treatment of Immune Globulin Infusion (Human), 10% (IGI, 10%) and to assess the mode of product administration.
Following a discussion with the FDA at the end of July 2012, all participants still active in the study stopped treatment with rHuPH20 to assure safety of the participants participating in the study and went into a safety follow-up.
During this safety follow-up period, participants underwent treatment with the licensed product IGI, 10% (Gammagard Liquid). The intravenous or subcutaneous administration route was at the discretion of the participant and the investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has been receiving a consistent dose of immunoglobulin G (IgG) with a non-Baxter product (Gammunex administered IV, Hizentra, or Privigen), administered in compliance with the respective product information, for a period of at least 3 months prior to screening. The average minimum pre-study dose over that interval was equivalent to 300 mg/kg BW/4 weeks and a maximum dose equivalent to 600 mg/kg BW/4 weeks at a dosing frequency as follows:
Exclusion Criteria:
Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):
Women of meeting any one of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.
Biological: Immune Globulin Infusion (Human), 10% · Biological: Recombinant human hyaluronidase
Subcutaneous administration will be used in Study Epochs 1 and 2.
Also known as: IGI, 10%
rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
Also known as: rHuPH20
Number of Related Systemic Adverse Events (Excluding Infections)
Time frame: 7 months (per subject)
Rate of Related Systemic Adverse Events (Excluding Infections) Per Infusion
A point estimate and 95% confidence interval for the rate of related systemic adverse events per infusion was derived using a Poisson model.
Time frame: 7 months (per subject)
Proportion of Subjects Who Achieve a Treatment Interval of 3 or 4 Weeks in Epoch 2
Time frame: 6 months (per subject)
Proportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks
Time frame: 6 months (per subject)
Number of Related Local Adverse Events (Excluding Infections)
Time frame: 7 months (per subject)
Rate of Related Local Adverse Events (Excluding Infections) Per Infusion
A point estimate and 95% confidence interval for the rate of related local adverse events per infusion was derived using a Poisson model.
Time frame: 7 months (per subject)
Number of All Related Adverse Events (Excluding Infections)
Time frame: 7 months (per subject)
Rate of All Adverse Events (Excluding Infections) Per Infusion
A point estimate and 95% confidence interval for the rate of adverse events per infusion was derived using a Poisson model.
Time frame: 7 months (per subject)
Number of Subjects Who Develop Neutralizing Antibodies to rHuPH20
Time frame: 7 months (per subject)
Trough Levels of Immunoglobulin G (IgG)
IgG trough levels at the beginning of Study Epoch 1 (previous immunoglobulin treatment) and at the end of Study Epoch 2 were analyzed.
Time frame: 7 months (per subject)
Number of Infusions Per Month in Epoch 1 and Epoch 2
Non-parametric descriptive statistics (median, range) are provided.
Time frame: 7 months (per subject)
Number of Infusion Sites (Needle Sticks) Per Month in Epoch 1 and Epoch 2
Non-parametric descriptive statistics (median, range) are provided.
Time frame: 7 months (per subject)
Duration of Infusion in Epoch 1 and Epoch 2
Non-parametric descriptive statistics (median, range) are provided.
Time frame: 7 months (per subject)
Maximum Infusion Rate in Epoch 1 and Epoch 2
Non-parametric descriptive statistics (median, range) are provided.
Time frame: 7 months (per subject)
Number of Weeks to Reach Final 3 or 4-week Dose Interval
Non-parametric descriptive statistics (median, range) are provided.
Time frame: 7 months (per subject)
Enrollment was conducted at 16 study sites in the US.
| Milestone | Subcutaneous Treatment With IGI, 10% and rHuPH20 |
|---|---|
| Started | 37 |
| Treated in epoch 1 | 37 |
| Completed | 36 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Subcutaneous Treatment With IGI, 10% and rHuPH20 |
|---|---|
| Started | 36 |
| Treated in epoch 2 | 36 |
| Completed | 1 |
| Not completed | 35 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Adverse event | 3 |
| Withdrew: Switch to safety follow-up | 26 |
| Milestone | Subcutaneous Treatment With IGI, 10% and rHuPH20 |
|---|---|
| Started | 37 |
| Treated in epoch 1 (ramp-up) | 37 |
| Completed epoch 1 (ramp-up) | 36 |
| Started epoch 2 | 36 |
| Treated in epoch 2 | 36 |
| Completed epoch 2 | 1 |
| Switch to safety follow-up | 26 |
| Completed safety follow-up | 24 |
| Completed | 25 |
| Not completed | 12 |
| Withdrew: Withdrawal by subject in epoch 1 | 1 |
| Withdrew: Withdrawal by subject in epoch 2 | 6 |
| Withdrew: Adverse event in epoch 2 | 3 |
| Withdrew: Withdrawal during safety-follow-up | 2 |
| adverse events | Safety Analysis Set (n=37) |
|---|---|
| Number of Related Systemic Adverse Events (Excluding Infections) | 59 |
A point estimate and 95% confidence interval for the rate of related systemic adverse events per infusion was derived using a Poisson model.
| adverse events | Safety Analysis Set (n=37) | Epoch 2 Data Set (n=36) |
|---|---|---|
| Epoch 1 | 0.250 (0.140 to 0.406) | 0.253 (0.141 to 0.413) |
| Epoch 2 | 0.377 (0.205 to 0.626) | 0.377 (0.205 to 0.626) |
| Epoch 1+2 | 0.324 (0.187 to 0.517) | 0.326 (0.186 to 0.522) |
| subjects | Epoch 2 Data Set (n=36) |
|---|---|
| 3 or 4-week treatment interval | 36 |
| 3-week treatment interval | 6 |
| 4-week treatment interval | 30 |
| subjects | Epoch 2 Data Set (n=36) |
|---|---|
| Proportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks | 1 |
| adverse events | Safety Analysis Set (n=37) |
|---|---|
| Number of Related Local Adverse Events (Excluding Infections) | 153 |
A point estimate and 95% confidence interval for the rate of related local adverse events per infusion was derived using a Poisson model.
| adverse events | Safety Analysis Set (n=37) | Epoch 2 Data Set (n=36) |
|---|---|---|
| Epoch 1 | 0.882 (0.581 to 1.271) | 0.880 (0.575 to 1.278) |
| Epoch 2 | 0.811 (0.541 to 1.160) | 0.811 (0.541 to 1.160) |
| Epoch 1+2 | 0.841 (0.587 to 1.159) | 0.840 (0.582 to 1.164) |
| adverse events | Safety Analysis Set (n=37) |
|---|---|
| Number of All Related Adverse Events (Excluding Infections) | 212 |
A point estimate and 95% confidence interval for the rate of adverse events per infusion was derived using a Poisson model.
| adverse events | Safety Analysis Set (n=37) | Epoch 2 Data Set (n=36) |
|---|---|---|
| Epoch 1 | 1.645 (1.221 to 2.157) | 1.653 (1.221 to 2.178) |
| Epoch 2 | 1.642 (1.164 to 2.235) | 1.642 (1.164 to 2.235) |
| Epoch 1+2 | 1.643 (1.235 to 2.132) | 1.646 (1.232 to 2.145) |
| subjects | Safety Analysis Set (n=37) |
|---|---|
| Number of Subjects Who Develop Neutralizing Antibodies to rHuPH20 | 0 |
IgG trough levels at the beginning of Study Epoch 1 (previous immunoglobulin treatment) and at the end of Study Epoch 2 were analyzed.
| g/L | Epoch 2 Data Set |
|---|---|
| At screening | 10.53 (9.46 to 11.73) |
| At end of Epoch 2 | 9.21 (8.28 to 10.25) |
Non-parametric descriptive statistics (median, range) are provided.
| infusions | Safety Analysis Set (n=37) |
|---|---|
| Epoch 1 | 2.90 (2.5 to 10.1) |
| Epoch 2 | 1.09 (0.6 to 2.0) |
Non-parametric descriptive statistics (median, range) are provided.
| infusion sites (needle sticks) | Safety Analysis Set (n=37) |
|---|---|
| Epoch 1 | 2.90 (2.5 to 10.1) |
| Epoch 2 | 1.12 (0.6 to 3.8) |
Non-parametric descriptive statistics (median, range) are provided.
| hours | Safety Analysis Set (n=37) |
|---|---|
| Epoch 1 | 1.23 (0.53 to 3.10) |
| Epoch 2 | 1.67 (0.80 to 3.55) |
Non-parametric descriptive statistics (median, range) are provided.
| mL/h | Safety Analysis Set (n=37) |
|---|---|
| Epoch 1 | 240.0 (60 to 300) |
| Epoch 2 | 300.0 (10 to 300) |
Non-parametric descriptive statistics (median, range) are provided.
| weeks | Epoch 2 Data Set (n=36) |
|---|---|
| 3-week dose interval | 3.0 (3 to 5) |
| 4-week dose interval | 3.0 (3 to 4) |
Collected over Overall: Approximately 1 year Per subject: 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epochs 1+2 (SC Treatment w/ IGI,10% and rHuPH20, n=37) | — | 0/37 (0%) | 30/37 (81.1%) |
| Safety Follow-up (n=26) | — | 1/26 (3.8%) | 10/26 (38.5%) |
| Event | Epochs 1+2 (SC Treatment w/ IGI,10% and rHuPH20, n=37) | Safety Follow-up (n=26) |
|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 0/37 | 1/26 |
| Event | Epochs 1+2 (SC Treatment w/ IGI,10% and rHuPH20, n=37) | Safety Follow-up (n=26) |
|---|---|---|
| Infusion site painGeneral disorders | 21/37 | 0/26 |
| Infusion site erythemaGeneral disorders | 11/37 | 0/26 |
| HeadacheNervous system disorders | 10/37 | 3/26 |
| Infusion site swellingGeneral disorders | 9/37 | 0/26 |
| FatigueGeneral disorders | 6/37 | 0/26 |
| NauseaGastrointestinal disorders | 5/37 | 1/26 |
| Infusion site pruritusGeneral disorders | 5/37 | 0/26 |
| PyrexiaGeneral disorders | 5/37 | 2/26 |
| SinusitisInfections and infestations | 5/37 | 2/26 |
| Upper respiratory tract infectionInfections and infestations | 1/37 | 3/26 |
| Age, Categorical(Participants) | Subcutaneous Treatment With IGI, 10% and rHuPH20 |
|---|---|
| <=18 years | 12 |
| Between 18 and 65 years | 22 |
| >=65 years | 3 |
| Age, Continuous(Years) | Subcutaneous Treatment With IGI, 10% and rHuPH20 |
|---|---|
| Median | 33.0 (6 to 69) |
| Sex: Female, Male(Participants) | Subcutaneous Treatment With IGI, 10% and rHuPH20 |
|---|---|
| Female | 21 |
| Male | 16 |
Ran from Dec 2011 to primary completion in Jan 2013, 12 months.
Results were first posted in Apr 2017, 4 years 3 months after primary completion. A results delay was requested in Sep 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Homo sapiens whole · Hyaluronidase (human recombinant)
Primary Immunodeficiency Diseases →